Allergan Sues Imprimis, Prescriber’s Choice, Sincerus Florida

September 8, 2017: By Jon Swedien

legal issuesAllergan filed lawsuits Sept. 7 against Imprimis Pharmaceuticals, Prescriber’s Choice, and Sincerus Florida, claiming they are illegally selling unapproved new drugs.

Allergan filed one complaint against Imprimis and one against both Prescriber’s Choice and Sincerus in the US District Court for the Central District of California.

Allergan’s complaints allege that the companies are illegally manufacturing and selling unapproved new drugs under the false guise that they are engaged in lawful compounding. Allergan also claims the three are engaging in false and misleading advertising and promotion of unapproved new drugs.

In a prepared statement, Allergan said it was taking this step because companies such as Allergan have a duty to put the safety of their patients first and it believes the three defendants are putting patients and physicians at risk.

Imprimis and Sincerus are US FDA-registered 503B outsourcing facilities. Prescriber’s Choice is a management company that assist physicians.

Allergan also claims that all three defendants are in violation of the Lanham Act, which protects against trademark infringements and state laws.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023